FDA Accepts Exelixis' NDA for Colorectal Cancer Combo, Boosting Valuation Focus
ByAinvest
Friday, Feb 6, 2026 6:35 pm ET1min read
EXEL--
FDA has accepted Exelixis' New Drug Application for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer, marking a significant regulatory milestone for the company. The NDA is supported by pivotal Phase 3 STELLAR-303 trial results, which suggested substantial clinical benefit. Exelixis shares have traded at $43.9 with a 31.1% return over the past year, highlighting the company's oncology focus and potential growth drivers.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet